

Name of Journal: *World Journal of Gastroenterology*

Manuscript NO: 50618

Manuscript Type: ORIGINAL ARTICLE

Basic Study

Oncogenic AMAM metallopeptidase domain 28 induces gemcitabine resistance and predicts poor prognosis in pancreatic cancer

Wei L *et al.* ADAM28 contributes to pancreatic cancer chemoresistance

Li Wei, Jing-Yun Wen, Jie Chen, Xiao-Kun Ma, Dong-Hao Wu, Zhan-Hong Chen, Jiang-Long Huang

ABSTRACT

Match Overview

1	Crossref 38 words Xiao Liu, Jun Wang, Mei Chen, Shilan Liu, Xiaodan Yu, Fuqiang Wen. "	1%
2	Internet 28 words www.ncbi.nlm.nih.gov	1%
3	Internet 24 words crawled on 18-Aug-2019 bmccancer.biomedcentral.com	1%
4	Internet 18 words crawled on 27-Aug-2019 bmcinfectdis.biomedcentral.com	1%
5	Internet 16 words crawled on 03-Jan-2014 www.biomedcentral.com	<1%
6	Internet 14 words crawled on 13-Jul-2018 www.thieme-connect.de	<1%
7	Internet 13 words crawled on 21-Feb-2019 tel.archives-ouvertes.fr	<1%
8	Internet 12 words crawled on 29-Aug-2019 tessera.spandidos-publications.com	<1%
9	Internet 12 words crawled on 03-Jun-2017 spandidos-publications.com	<1%
10	Internet 12 words crawled on 06-Jun-2017 dibernardo.tigem.it	<1%
11	Internet 11 words crawled on 15-May-2018 www.spandidos-publications.com	<1%



All

Images

Videos

翻译成中文

关闭取词

5,010 Results

Any time ▾

Heterogeneity analysis of Metastasis Associated in Colon ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4371627>

Heterogeneity analysis of Metastasis Associated in Colon Cancer 1 (MACC1) for survival prognosis of colorectal cancer patients: a retrospective cohort study ... esophagus , pancreatic and hepatobiliary ... Liu P, Huang H, Liao W, et al. Metastasis-associated in colon cancer-1 upregulation predicts a poor prognosis of gastric cancer, and ...

Cited by: 22

Author: Viktor H Koelzer, Pia Herrmann, Inti Zlobe...

Publish Year: 2015

TOP2A induces malignant character of pancreatic cancer ...

<https://www.sciencedirect.com/science/article/pii/S0925443917303836>

3.1. TOP2A is up-regulated in pancreatic cancer and is correlated with poor survival. In order to identify genes associated with progression and prognosis of pancreatic cancer, we analyzed cohort 1 (GSE62452) in GEO database, which contains 130 samples (Tumor = 69, Adjacent non-tumor = 61).

Cited by: 4

Author: Yao-fei Pei, Xi-min Yin, Xi-qiang Liu

Publish Year: 2018

Managing Pancreatic Adenocarcinoma: A Special Focus in ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881540>

Despite all progress in medicine and in understanding the molecular mechanisms of carcinogenesis, pancreatic cancer still has a poor prognosis, the median survival after diagnosis being around 3 to 6 months and the survival rate of 5 years being less than 4%.

Cited by: 7

Author: Marta Passadouro, Henrique Faneca

Publish Year: 2016

Pathological and therapeutic aspects of matrix ...

<https://onlinelibrary.wiley.com/doi/pdf/10.1111/ajco.13165> ▾

levels have been shown to be associated with metastasis and poor prognosis in several types of cancer including OS.^{15,16} Thus, ... Wang L, Liu W, Tang H, et al. DRP5 is involved in cancer cell growth and predicts poor prognosis in human osteosarcoma. Cancer Med. 2017;6:982-993. ... vivo tumor growth in human pancreatic adenocarcinoma. Mol Cancer

(PDF) Advancement of NF-κB Signaling Pathway: A Novel ...

https://www.researchgate.net/publication/329437704_Advancement_of_NF-κB_Signaling...



All

Images

Videos

翻译成中文

关闭取词

27,700 Results

Any time ▾

Overexpressed EDIL3 predicts poor prognosis and promotes ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826201>

Jan 26, 2016 · INTRODUCTION. **Pancreatic** ductal adenocarcinoma (PDAC) remains one of the most deadly malignancies with frequent metastasis and recurrence []. Most cases with **pancreatic cancer** are diagnosed in advanced stages and are ineligible for potentially curative resection, which lead to a **poor prognosis** with a 5-year survival rate of 6% in all patients []. ...

Cited by: 8

Author: Shu-Heng Jiang, Yang Wang, Jian-Yu Yang, ...

Publish Year: 2016

The oncogenic receptor ErbB2 modulates gemcitabine and ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4484424>

May 10, 2015 · We had also previously showed that the human mucin MUC4 forms a complex at the membrane with the **oncogenic receptor ErbB2** and that loss of MUC4 in **pancreatic cancer** cells led to an increased sensitivity to **gemcitabine** and an increased expression of hCNT1 correlated to cell survival . Altogether, this supports the hypothesis of ErbB2 and MUC4 acting as a complex to maintain a **drug resistant phenotype**.

Cited by: 9

Author: Nicolas Skrypek, Romain Vasseur, Audrey ...

Publish Year: 2015

Disrupting glutamine metabolic pathways to sensitize ...

<https://www.nature.com/articles/s41598-017-08436-6>

Aug 11, 2017 · **Pancreatic cancer** is a lethal disease with **poor prognosis**. **Gemcitabine** has been the first line systemic treatment for **pancreatic cancer**. However, the rapid development of drug **resistance** ...

Cited by: 4

Author: Ru Chen, Lisa A Lai, Yumi Sullivan, Melissa ...

Publish Year: 2017 Author: Ru Chen

HNF1A inhibition induces the resistance of pancreatic ...

<https://www.sciencedirect.com/science/article/pii/S2352396419303147>

Pancreatic ductal adenocarcinoma (PDAC) is an **aggressive disease** with **poor prognosis**, and **gemcitabine-based chemotherapy** remains an effective option for the majority of **PDAC patients**. Hepatocyte nuclear factor 1 α (HNF1A) is a **tumor-suppressor** in PDAC, but its role in **gemcitabine chemoresistance of PDAC** has not been clarified.

Author: Yanan Lu, Dongni Xu, Jintao Peng, Zhao... Publish Year: 2019

GATA1 Promotes Gemcitabine Resistance in Pancreatic Cancer ...

<https://www.hindawi.com/journals/jo/2019/9474273> ▾